Premium
Guidelines for the diagnosis and treatment of acute non‐variceal upper gastrointestinal bleeding (2015, Nanchang, China)
Author(s) -
Bai Yu,
Li Zhao Shen
Publication year - 2016
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12319
Subject(s) - medicine , etiology , upper gastrointestinal bleeding , gastrointestinal bleeding , medline , clinical trial , endoscopy , randomized controlled trial , intensive care medicine , general surgery , gastroenterology , political science , law
Acute non‐variceal upper gastrointestinal bleeding (ANVUGIB) is one of the most common medical emergencies in China and worldwide. In 2009, we published the “Guidelines for the diagnosis and treatment of acute non‐variceal upper gastrointestinal bleeding” for the patients in China; however, during the past years numerous studies on the diagnosis and treatment of ANVUGIB have been conducted, and the management of ANVUGIB needs to be updated. The guidelines were updated after the databases including PubMed, Embase and CNKI were searched to retrieve the clinical trials on the management of ANVUGIB. The clinical trials were evaluated for high‐quality evidence, and the advances in definitions, diagnosis, etiology, severity evaluation, treatment and prognosis of ANVUGIB were carefully reviewed, the recommendations were then proposed. After several rounds of discussions and revisions among the national experts of digestive endoscopy, gastroenterology, radiology and intensive care, the 2015 version of “Guidelines for the diagnosis and treatment of acute non‐variceal upper gastrointestinal bleeding” was successfully developed by the Chinese Journal of Internal Medicine, National Medical Journal of China, Chinese Journal of Digestion and Chinese Journal of Digestive Endoscopy. It shall be noted that although much progress has been made, the clinical management of ANVUGIB still needs further improvement and refinement, and high‐quality randomized trials are required in the future.